Tumor-infiltrating lymphocytes (TILs) have been shown to have prognostic and predictive value in both adjuvant [2–4] and neoadjuvant settings [5–7] in breast cancer, especially in TN and HER2 breast cancers. The gene discussed is ERBB2; the disease is breast cancer.